Previous Article | Next Article 
Journal of Clinical Microbiology, June 2000, p. 2409-2411, Vol. 38, No. 6
0095-1137/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Limitations of Vitek GPS-418 Cards in Exact
Detection of Vancomycin-Resistant Enterococci with the
vanB Genotype
Tadashi
Okabe,1
Kozue
Oana,2
Yoshiyuki
Kawakami,2,*
Masaru
Yamaguchi,1
Yuko
Takahashi,1
Yukie
Okimura,1
Takayuki
Honda,3 and
Tsutomu
Katsuyama3
Central Clinical Laboratories, Shinshu
University Hospital,1 Division of
Clinical Microbiology, Department of Medical Technology, School of
Allied Medical Sciences, Shinshu University,2
and Department of Laboratory Medicine, Shinshu University
School of Medicine,3 Matsumoto, Nagano,
390-8621, Japan
Received 8 November 1999/Returned for modification 11 January
2000/Accepted 21 March 2000
 |
ABSTRACT |
The susceptibilities of 20 strains of vancomycin-resistant
enterococci (VRE) with the vanB genotype obtained by using
Vitek GPS-418 cards were compared with those obtained by the broth
dilution method of the National Committee for Clinical Laboratory
Standards (NCCLS) (approved standard M7-A4) and with those obtained by
the agar screen method using bile esculin azide agar containing 6 µg
of vancomycin per ml. Although both the broth dilution and agar screen
methods disclosed no discordance, Vitek GPS-418 cards yielded a very
major error compared with the results obtained by the reference broth
dilution method of the NCCLS. Vitek GPS-418 cards were therefore found
to have considerable room for improvement for the accurate detection of
vanB VRE strains.
 |
TEXT |
Since the late 1980s, strains of
vancomycin-resistant enterococci (VRE) have emerged as significant
causes of nosocomial infections and colonizations with increasing
frequency in every part of the world (2, 4, 12, 14). Indeed,
there is no proven chemotherapy for an infection, since VRE strains
have been demonstrated to be resistant not only to vancomycin but also
to multidrug therapy (11). Two genetically distinct forms of
resistance, designated the vanA and vanB
genotypes, are recognized to be clinically important, although
intrinsic resistance occurs in some enterococcal species (vanC genotype) and a third form of resistance
(vanD genotype) has emerged (10). Moreover, an
additional fourth type of the resistance (vanE genotype) has
recently been reported (1).
In fact, infectious diseases due to these VRE strains have become a
serious problem (2, 4, 5). To control the transmission of
VRE strains and to control successive outbreaks of their
cross-infections in any medical facility (6, 7, 9), the
necessity of evaluating the rapidity and reliability of the detection
methods for VRE strains has been emphasized for clinical microbiology
laboratories. Although genetic methods for the detection of the
vanA and/or vanB gene by PCR have been evaluated
with considerable certainty, routine tests, such as the E-test (AB
Biodisk, Solna, Sweden), sensi-disk (Becton Dickinson Microbiology
Systems, Sparks, Md.), and agar screen test using plates containing 6 µg of vancomycin per ml, are already commercially available for the
confirmation of the phenotypes of VRE strains.
In Japan, many laboratories have adopted the Automicrobic System (Vitek
Systems, Hazelwood, Mo.) for the detection of VRE strains in routine
clinical microbiology. The Vitek GPS card has successively improved
from the Vitek GPS-TA card with 30 wells released in July 1997 (used in
Japan) to the Vitek GPS-101 card with 45 wells (used in the United
States) to the Vitek GPS-418 card with 45 wells (used in Japan)
released in February 1999. The abilities of both the Vitek GPS-101 and
Vitek 418 cards to determine susceptibility to vancomycin were improved
from a three-well method to a four-well method. Vitek GPS-101 cards
used in the United States were the same as Vitek GPS-418 cards used in
Japan except for a minor change in the antimicrobials other than
vancomycin and have already been evaluated to have been significantly
improved in the detection of VRE with the VanB phenotype
(3). In fact, H. P. Entdz et al. emphasized that 15 investigated VRE strains with the vanB genotype were all
correctly identified as VRE strains without exception by the Vitek
GPS-101 card (3). Our report focused on the reevaluation,
with 20 Japanese VRE strains with the vanB genotype, of the
Vitek GPS-418 card (software configuration version VTK-R06.01) by
comparing it with the cards provided both by the broth dilution method
of the National Committee for Clinical Laboratory Standards (NCCLS)
(approved standard M7-A4) (8) and by the sensi-disk method.
A total of 20 VRE strains with the vanB genotype from
different patients were our stock cultures and were stored in Microbank vials (Pro-Lab Diagnostic, Ontario, Canada) at
83°C in a deep freezer. All of the strains examined were reidentified as
Enterococcus faecalis by the Vitek GPI card, which also
reconfirmed them to be VRE strains with the vanB genotype by
detecting the vanB gene(s) by a PCR procedure
(16) to coamplify vanB-specific genes of enterococci. Susceptibility tests were carried out in duplicate by the
three methods, i.e., the Vitek GPS card method, the sensi-disk method,
and the broth dilution method of NCCLS approved standard M7-A4
(8). The Vitek GPS card method was carried out using GPS-418
cards, as indicated in the instructions provided with the system. The
sensi-disk method for susceptibility testing was also performed as
indicated in the instructions provided by the manufacturer. The broth
dilution method for the reference MICs of vancomycin for 20 VRE strains
with the vanB genotype were done in accordance with the
guidelines of NCCLS approved standard M7-A4 (8) on
cation-adjusted Mueller-Hinton broth (Difco Laboratories, Detroit,
Mich.). The results were read after 24 h of incubation at 37°C.
VRE screen agars containing 6 µg of vancomycin (Nippon Becton
Dickinson and Company, Ltd., Tokyo, Japan) per ml were used with an
inoculum size of 10 µl of a McFarland 0.5 standard suspension as
described by Tenover et al. (13). The NCCLS breakpoints were
used for the interpretation of the MICs (8).
Duplicate results obtained with each procedure were then compared, and
any strain with an aberrant or questionable reaction was retested by
the three methods for the susceptibility properties in discrepancy. A
very major error was defined as an isolate which was resistant by the
reference dilution method but susceptible by the test method. A major
error was defined as an isolate which was susceptible by the reference
dilution method but resistant by the test method. A minor error was
defined as a discrepancy between the results of the reference dilution
method and the test method corresponding to one interpretation category.
Table 1 demonstrates the distribution of
MICs of vancomycin for the 20 strains with the vanB genotype
tested. Shown are the MICs obtained by the reference broth dilution
method of NCCLS approved standard M7-A4 (8). The vast
majority (17 out of 20 strains) of MICs fell below 32 µg/ml, ranging
from 8 to 32 µg/ml. On the other hand, the Vitek GPS-418 card method
yielded an apparently discrepant MIC of less than 0.5 µg/ml, although
it was observed with only a single strain (Table 1). This discrepant
finding was always consistent even after the trials were repeated five times with Vitek GPS-418 cards. The MIC for this strain was 16 µ/ml
by the reference broth dilution method of NCCLS approved standard M7-A4
(8).
Table 2 represents the incidence of very
major, major, and minor errors of the separate methods in comparison
with results of the reference broth dilution method of NCCLS approved
standard M7-A4 (8). Both the sensi-disk and agar screen
methods were 100% sensitive with each other for the detection of
vanB genes in the 20 VRE strains examined. As shown in Table
2, the results obtained by the sensi-disk method corresponded well to
those obtained by the broth dilution method of NCCLS approved standard
M7-A4 (8), and even a minor error was not observed. In
addition, the agar screen method using VRE screen agar supplemented
with vancomycin (Nippon Becton Dickinson and Company, Ltd.) at a final concentration of 6 µg/ml exceptionally allowed the growth of all the
VRE strains investigated. It is very encouraging that both the
sensi-disk method and the agar screen method correctly identified all
of the 20 VRE strains examined, thus confirming the results of some
recent evaluation studies (3, 15, 16), but these tests were
time-consuming nevertheless.
Indeed, Vitek systems have been widely adopted by many microbiology
laboratories for the rapid identification and determination of
susceptibilities of pathogens, including VRE strains. In order not only
to treat VRE-infected patients but also to implement appropriate
control measures to prevent the spread of VRE strains, rapid and
accurate identification of VRE-colonized patients is essential. N. Yamane et al. (16) evaluated several automated methods, such
as the Microscan conventional- and rapid-panel methods and Vitek GPS-TA
cards, and found that every automated method tested was shown to yield
a high error rate. Recently, H. P. Entdz et al. (3)
pointed out that newly developed Vitek GPS-101 cards with 45 wells have
been significantly improved and that they successfully detected all of
the VRE strains with the vanB genotype tested (15 out of 15 strains).
During the course of this reevaluation study, however, the very major
error (only 1 out of 20 strains detected successfully) that only the
Vitek GPS-418 cards revealed was noteworthy. It should be emphasized
that there still exists much room for improvement in Vitek GPS-418
cards for the accurate detection of VRE strains with the
vanB genotype. Significant improvement of Vitek GPS cards for the exact detection of VRE strains is urgently desired.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Division of
Clinical Microbiology, Department of Medical Technology, School of
Allied Medical Sciences, Shinshu University, Matsumoto 390-8621, Japan. Phone: 81-263-37-2381. Fax: 81-263-37-2370. E-mail:
yk23724{at}gipac.shinshu-u.ac.jp.
 |
REFERENCES |
| 1.
|
Casadewall, B., and P. Courvalin.
1999.
Characterization of the vanD glycopeptide resistance gene cluster from Enterococcus faecium BM4339.
J. Bacteriol.
181:3644-3648[Abstract/Free Full Text].
|
| 2.
|
Centers for Disease Control and Prevention.
1993.
Nosocomial enterococci resistant to vancomycin United States, 1989-1993.
Morb. Mortal. Wkly. Rep.
42:597-599[Medline].
|
| 3.
|
Endtz, H. P.,
N. Van Den Braak,
A. Van Belkum,
W. H. Goessens,
D. Kreft,
A. B. Stroebel, and H. A. Verbrugh.
1998.
Comparison of eight methods, including use of the new Vitek GPS-101 card, to detect vancomycin resistance in enterococci.
J. Clin. Microbiol.
36:592-594[Abstract/Free Full Text].
|
| 4.
|
Goetz, A. M.,
J. D. Rihs,
M. M. Wagener, and R. R. Muder.
1998.
Infection and colonization with vancomycin-resistant Enterococcus faecium in an acute care Veterans Affairs medical center: a 2-year survey.
Am. J. Infect. Control.
26:558-562[CrossRef][Medline].
|
| 5.
|
Jochimsen, E. M.,
L. Fish,
K. Manning,
S. Young,
D. A. Singer,
R. Baker, and W. R. Jarvis.
1999.
Control of vancomycin-resistant enterococci at a community hospital: efficacy of patient and staff cohorting.
Infect. Control Hosp. Epidemiol.
20:106-109[CrossRef][Medline].
|
| 6.
|
Malik, R. K.,
M. A. Montecalvo,
M. R. Reale,
K. Li,
M. Maw,
J. L. Munoz,
C. Gedris,
K. van Horn,
K. A. Carnevale,
M. H. Levi, and H. S. Dweck.
1999.
Epidemiology and control of vancomycin-resistant enterococci in a regional neonatal intensive care unit.
Pediatr. Infect. Dis. J.
18:352-356[CrossRef][Medline].
|
| 7.
|
Marguerite, F.,
P. Bruno,
R. Peter,
F. S. Daniel, and C. Patrice.
1999.
VanE, a new type of acquired glycopeptide resistance in Enterococcus faecalis BM4405.
Antimicrob. Agents Chemother.
43:2161-2164[Abstract/Free Full Text].
|
| 8.
|
National Committee for Clinical Laboratory Standards.
1997.
Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 3rd ed.
Approved standard M7-A4. National Committee for Clinical Laboratory Standard, Wayne, Pa.
|
| 9.
|
Nourse, C.,
H. Murphy,
C. Byrne,
A. Omeara,
F. Breatnach,
M. Kaufmann,
A. Clarke, and K. Butler.
1998.
Control of a nosocomial outbreak of vancomycin resistant Enterococcus faecium in a paediatric oncology unit: risk factors for colonisation.
Eur. J. Pediatr.
157:20-27[CrossRef][Medline].
|
| 10.
|
Perichon, B.,
P. Reynolds, and P. Courvalin.
1997.
VanD-type glycopeptide-resistant Enterococcus faecium BM4339.
Antimicrob. Agents Chemother.
41:2016-2018[Abstract].
|
| 11.
|
Saraiva, I. H.,
R. N. Jones,
M. Erwin, and H. S. Sader.
1997.
Evaluation of antimicrobial sensitivity of 87 clinical isolates of vancomycin-resistant enterococci.
Rev. Assoc. Med. Bras.
43:217-222.
|
| 12.
|
Schuster, F.,
U. B. Graubner,
I. Schmid,
M. Weiss, and B. H. Belohradsky.
1998.
Vancomycin-resistant-enterococci colonization of 24 patients on a pediatric oncology unit.
Klin. Padiatr.
210:261-263[Medline].
|
| 13.
|
Tenover, F. C.,
J. Tokars,
J. M. Swenson,
S. Paul,
K. Spitalny, and W. Jarvis.
1993.
Ability of laboratories to detect antimicrobial agent-resistant enterococci.
J. Clin. Microbiol.
32:1700-1704[Abstract/Free Full Text].
|
| 14.
|
Tokars, J. I.,
S. Satake,
D. Rimland,
L. Carson,
E. R. Miller,
E. Killum,
R. L. Sinkowitz Cochran,
M. J. Arduino,
F. C. Tenover,
B. Marston, and W. R. Jarvis.
1999.
The prevalence of colonization with vancomycin-resistant Enterococcus at a Veterans' Affairs institution.
Infect. Control Hosp. Epidemiol.
20:171-175[CrossRef][Medline].
|
| 15.
|
Van Horn, K. G.,
C. A. Gedris,
K. M. Rodney, and J. B. Mitchell.
1996.
Evaluation of commercial vancomycin agar screen plates for detection of vancomycin-resistant enterococci.
J. Clin. Microbiol.
34:2042-2044[Abstract].
|
| 16.
|
Yamane, N.,
S. Mitagawa,
I. Nakasone,
F. Sakamoto, and M. Tosaka.
1997.
Laboratory-evaluation of antimicrobial susceptibility testings to detect vancomycin-resistant enterococci.
Jpn. J. Clin. Pathol. (Rinsho Byori)
45:381-390. (In Japanese with English summary.)
|
Journal of Clinical Microbiology, June 2000, p. 2409-2411, Vol. 38, No. 6
0095-1137/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Abele-Horn, M., Hommers, L., Trabold, R., Frosch, M.
(2006). Validation of VITEK 2 Version 4.01 Software for Detection, Identification, and Classification of Glycopeptide-Resistant Enterococci. J. Clin. Microbiol.
44: 71-76
[Abstract]
[Full Text]